...
search icon
algs-img

Aligos Therapeutics Inc, Common Stock

ALGS

NAQ

$18.725

-$2.13

(-10.22%)

1D
Industry: Biotechnology Sector: Health Care

Analyst Forecast

Price Chart

Key Metrics

Market Cap info-icon
This is a company’s total value as determined by the stock market. It is calculated by multiplying the total number of a company's outstanding shares by the current market price of one share.
$74.81M
P/E Ratio info-icon
This is the ratio of a security’s current share price to its earnings per share. This ratio determines the relative value of a company’s share.
0
Volume info-icon
This is the total number of shares traded during the most recent trading day.
211.38K
Avg Volume info-icon
This is the average number of shares traded during the most recent 30 days.
0
Dividend Yield info-icon
This ratio shows how much income you earn in dividend payouts per year for every dollar invested in the stock (or the stock’s annual dividend payment expressed as a percentage of its current price).
0.00%
Beta info-icon
This measures the expected move in a stock’s price relative to movements in the overall market. The market, such as the S&P 500 Index, has a beta of 1.0. If a stock has a Beta greater (or lower) than 1.0, it suggests that the stock is more (or less) volatile than the broader market.
2.46
52-week Range info-icon
This shows the range of the stock’s price between the 52-week high (the highest price of the stock for the past 52 weeks) and the 52-week low (the lowest price of the stock for the past 52 weeks).
$6.76 L
$46.8 H
$18.725

About Aligos Therapeutics Inc, Common Stock

Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapeutics to address unmet medical needs in viral and liver diseases. Its drug candidate, ALG-055009, a small molecule THR-ß agonist that is in the Phase 2a clinical trial for the treatment of non-alcoholic steatohepatitis (NASH). The company also develops ALG-000184, a capsid assembly modulator, which is completed Phase 1b clinical trial to treat chronic hepatitis B (CHB); and ALG-125755, a siRNA drug candidate, which is in Phase I clinical trial for the treatment of CHB. In addition, it develops ALG-097558, which is in Phase 2 clinical trial for the treatment of coronavirus. The company has entered into license and research collaboration agreement with Merck to discover, research, optimize, and develop oligonucleotides directed against a NASH; license agreement with Emory University to provide hepatitis B virus capsid assembly modulator technology; license agreement with Luxna Biotech Co., Ltd. to develop and commercialize products containing oligonucleotides targeting hepatitis B virus genome; and research, licensing, and commercialization agreement with Katholieke Universiteit Leuven to develop coronavirus protease inhibitors. It also has a clinical collaboration with Xiamen Amoytop Biotech Co., Ltd. Aligos Therapeutics, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California. more

Industry: BiotechnologySector: Health Care

Returns

Time FrameALGSSectorS&P500
1-Week Return-0.76%0.57%0.11%
1-Month Return-38.3%3.31%1.23%
3-Month Return14.56%3.04%3.39%
6-Month Return43.99%-4.66%9.31%
1-Year Return30.31%1.44%22.95%
3-Year Return-65.1%15.75%42.13%
5-Year Return-94.38%42.42%81.24%

Financials

Dec '19Dec '20Dec '21Dec '22Dec '235YR TREND
Total Revenue-(10.55M)4.36M13.91M15.53M[{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":-67.92,"profit":false},{"date":"2021-12-31","value":28.07,"profit":true},{"date":"2022-12-31","value":89.56,"profit":true},{"date":"2023-12-31","value":100,"profit":true}]
Cost of Revenue2.30M3.33M104.15M3.67M3.07M[{"date":"2019-12-31","value":2.21,"profit":true},{"date":"2020-12-31","value":3.19,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":3.53,"profit":true},{"date":"2023-12-31","value":2.95,"profit":true}]
Gross Profit(2.30M)(10.55M)4.36M13.91M12.46M[{"date":"2019-12-31","value":-16.53,"profit":false},{"date":"2020-12-31","value":-75.85,"profit":false},{"date":"2021-12-31","value":31.34,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":89.6,"profit":true}]
Gross Margin-100.00%100.00%100.00%80.24%[{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":80.24,"profit":true}]
Operating Expenses54.04M97.83M132.68M111.49M103.66M[{"date":"2019-12-31","value":40.73,"profit":true},{"date":"2020-12-31","value":73.74,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":84.03,"profit":true},{"date":"2023-12-31","value":78.12,"profit":true}]
Operating Income(54.04M)(97.83M)(128.32M)(97.58M)(88.13M)[{"date":"2019-12-31","value":-5404300000,"profit":false},{"date":"2020-12-31","value":-9783400000,"profit":false},{"date":"2021-12-31","value":-12832100000,"profit":false},{"date":"2022-12-31","value":-9758000000,"profit":false},{"date":"2023-12-31","value":-8812700000,"profit":false}]
Total Non-Operating Income/Expense3.43M(21.10M)264.00K3.28M2.49M[{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":-615.76,"profit":false},{"date":"2021-12-31","value":7.71,"profit":true},{"date":"2022-12-31","value":95.74,"profit":true},{"date":"2023-12-31","value":72.56,"profit":true}]
Pre-Tax Income(52.18M)(108.38M)(128.19M)(95.94M)(86.88M)[{"date":"2019-12-31","value":-5217900000,"profit":false},{"date":"2020-12-31","value":-10838200000,"profit":false},{"date":"2021-12-31","value":-12818900000,"profit":false},{"date":"2022-12-31","value":-9594000000,"profit":false},{"date":"2023-12-31","value":-8688400000,"profit":false}]
Income Taxes85.00K161.00K143.00K106.00K795.00K[{"date":"2019-12-31","value":10.69,"profit":true},{"date":"2020-12-31","value":20.25,"profit":true},{"date":"2021-12-31","value":17.99,"profit":true},{"date":"2022-12-31","value":13.33,"profit":true},{"date":"2023-12-31","value":100,"profit":true}]
Income After Taxes(52.26M)(108.54M)(128.33M)(96.05M)(87.68M)[{"date":"2019-12-31","value":-5226400000,"profit":false},{"date":"2020-12-31","value":-10854300000,"profit":false},{"date":"2021-12-31","value":-12833200000,"profit":false},{"date":"2022-12-31","value":-9604600000,"profit":false},{"date":"2023-12-31","value":-8767900000,"profit":false}]
Income From Continuous Operations(52.26M)(108.54M)(128.33M)(96.05M)(87.68M)[{"date":"2019-12-31","value":-5226400000,"profit":false},{"date":"2020-12-31","value":-10854300000,"profit":false},{"date":"2021-12-31","value":-12833200000,"profit":false},{"date":"2022-12-31","value":-9604600000,"profit":false},{"date":"2023-12-31","value":-8767900000,"profit":false}]
Income From Discontinued Operations-----[{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}]
Net Income(52.26M)(108.54M)(128.33M)(96.05M)(87.68M)[{"date":"2019-12-31","value":-5226400000,"profit":false},{"date":"2020-12-31","value":-10854300000,"profit":false},{"date":"2021-12-31","value":-12833200000,"profit":false},{"date":"2022-12-31","value":-9604600000,"profit":false},{"date":"2023-12-31","value":-8767900000,"profit":false}]
EPS (Diluted)-(13.03)(3.20)(2.26)(1.59)[{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":-1303,"profit":false},{"date":"2021-12-31","value":-320,"profit":false},{"date":"2022-12-31","value":-226,"profit":false},{"date":"2023-12-31","value":-159,"profit":false}]

Ratios

Liquidity

These ratios help you determine the liquidity of the company. Higher is better.

ALGS
Cash Ratio 3.58
Current Ratio 3.81

Asset Efficiency

These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.

ALGS
ROA (LTM) -67.32%
ROE (LTM) -146.69%

Liabilities

These ratios help you understand the company's liabilities, gauging the riskiness of the investment.

ALGS
Debt Ratio Lower is generally better. Negative is bad. 0.43
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. 0.57

Valuation

These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.

ALGS
Trailing PE NM
Forward PE NM
P/S (TTM) 12.47
P/B 1.59
Price/FCF NM
EV/R 2.35
EV/Ebitda 0.57

FAQs

What is Aligos Therapeutics Inc share price today?

Aligos Therapeutics Inc (ALGS) share price today is $18.725

Can Indians buy Aligos Therapeutics Inc shares?

Yes, Indians can buy shares of Aligos Therapeutics Inc (ALGS) on Vested. To buy Aligos Therapeutics Inc from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in ALGS stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.

Can Fractional shares of Aligos Therapeutics Inc be purchased?

Yes, you can purchase fractional shares of Aligos Therapeutics Inc (ALGS) via the Vested app. You can start investing in Aligos Therapeutics Inc (ALGS) with a minimum investment of $1.

How to invest in Aligos Therapeutics Inc shares from India?

You can invest in shares of Aligos Therapeutics Inc (ALGS) via Vested in three simple steps:

  • Click on Sign Up or Invest in ALGS stock at the top of this page
  • Breeze through our fully digital and secure KYC process and open your US Brokerage account in a few minutes
  • Transfer USD funds to your US Brokerage account and start investing in Aligos Therapeutics Inc shares
What is Aligos Therapeutics Inc 52-week high and low stock price?

The 52-week high price of Aligos Therapeutics Inc (ALGS) is $46.8. The 52-week low price of Aligos Therapeutics Inc (ALGS) is $6.76.

What is Aligos Therapeutics Inc price-to-book (P/B) ratio?

The price-to-book (P/B) ratio of Aligos Therapeutics Inc (ALGS) is 1.59

What is the Market Cap of Aligos Therapeutics Inc?

The market capitalization of Aligos Therapeutics Inc (ALGS) is $74.81M

What is Aligos Therapeutics Inc’s stock symbol?

The stock symbol (or ticker) of Aligos Therapeutics Inc is ALGS

Signup to access all features and start your US investing journey!

  • Open your account in minutes
  • Take your portfolio global, starting at just $1
Get started

Add ticker to compare

Scroll to Top